An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

Frontiers Health is back, bringing together healthcare innovators from around the world to exchange insights and discuss some ...

The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens. The technology proved ...

At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...

According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local ...

Researchers from Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center (BMC) reviewed cancer ...

Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

The oncology landscape is evolving, with a marked rise in cancer incidence among young adults globally. This challenges the traditional view of cancer as primarily an ailment of the elderly. The ...